Investigational drug · Phase 3
HM11260C
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes, Obesity.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
8
Any phase or sponsor naming "HM11260C"
First trial start
2024
Jan 3, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HM11260C", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes
- Obesity
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "HM11260C" as an intervention, largest first.
- A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes MellitusPivotal-lookingCompleted
Hanmi Pharmaceutical Company LimitedIndustry
NCT06174779 · 448 participants · Start Jan 3, 2024 · Primary completion Aug 14, 2025
Drug: HM11260C; Placebo · For: Obesity
Sites: Seoul, South Korea
- Effect of LAPS-Exendin on Body Weight in Obese PopulationPivotal-lookingCompleted
Hanmi Pharmaceutical Company LimitedIndustry
NCT02075281 · 297 participants · Start Feb 2014 · Primary completion Jan 2015
Drug: HM11260C; Placebo · For: Obesity
Sites: Los Angeles, California
- Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 DiabetesPivotal-lookingCompleted
Hanmi Pharmaceutical Company LimitedIndustry
NCT02057172 · 254 participants · Start Jan 2014 · Primary completion Oct 2014
Drug: HM11260C; liraglutide and 1 more · For: Type 2 Diabetes
Sites: CA, California
- Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 DiabetesPivotal-lookingCompleted
Hanmi Pharmaceutical Company LimitedIndustry
NCT02081118 · 209 participants · Start Feb 2014 · Primary completion Mar 2015
Drug: HM11260C; Placebo · For: Type 2 Diabetes
Sites: Miami, Florida
- A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and DapagliflozinPivotal-lookingRecruiting
Hanmi Pharmaceutical Company LimitedIndustry
NCT07379333 · 118 participants (planned) · Start Apr 13, 2026 · Primary completion Nov 2027
Drug: HM11260C; Placebo · For: Type 2 Diabetes
Sites: Gyeonggi-do, South Korea
Hanmi Pharmaceutical Company LimitedIndustry
NCT01452451 · 72 participants · Start Dec 2011 · Primary completion Jun 2013
Drug: HM11260C; Placebo · For: Diabetes Mellitus
Sites: Ohio City, Ohio
Hanmi Pharmaceutical Company LimitedIndustry
NCT02059564 · 44 participants (planned) · Start Dec 2013 · Primary completion Oct 2014
Drug: HM11260C; Placebo and 1 more · For: Diabetes Mellitus
Sites: California City, California
Hanmi Pharmaceutical Company LimitedIndustry
NCT01093729 · 41 participants · Start Feb 2010 · Primary completion Oct 2010
Drug: HM11260C; HM11260C and 3 more · For: Healthy
Newest research
PubMed records naming it or its code names, newest first.
- Exposure-driven tolerance modeling of efpeglenatide-induced nausea or vomiting using repeated time-to-event analysis: implications for dose-escalation strategies.
Seo J, Choi S, Kim N, et al. · Front Pharmacol 2026
- Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes.
Choi S, Seo J, Park S, et al. · Front Pharmacol 2025
Also in development for Type 2 Diabetes
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.